Please provide your email address to receive an email when new articles are posted on . Gastroenterologists and hepatologists were leaders in nonalcoholic steatohepatitis diagnosis and viewed as ...

In a potential breakthrough for diagnosis and treatment development of liver disease, the Biomarkers Consortium’s Noninvasive Biomarkers of Metabolic Liver Disease (NIMBLE) project demonstrated that a ...

Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D. Results ...

Please provide your email address to receive an email when new articles are posted on . In a multicenter study, researchers identified two novel protein biomarkers (PLIN2 and RAB14) that demonstrated ...

New test featured today in Gut, a leading international journal published by BMJ, uses A.I. to accurately predict the stages of the whole spectrum of liver diseases, from NAFLD to NASH and liver ...

Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), is spectrum of diseases that ranges from non-alcoholic fatty liver (NAFL) to ...

A new non-invasive method of predicting the risk of developing a severe form of liver disease could ensure patients receive early and potentially life-saving medical intervention before irreversible ...

Adults in their 40s and 50s are getting diagnosed with Stage 3 or Stage 4 liver cirrhosis, even though they have never consumed alcohol to excess and have never felt any symptoms of the disease.